Carbogen Amcis is planning significant investment after years of constant growth
Swiss-based CDMO Carbogen
Amcis has announced two major expansion projects over the next four years at a cost of over € 90 million . This follows six years of constant growth for the company , a subsidiary of India ’ s Dishman Group ,
which aims to address continually growing market demand . At Hunzenschwil in Switzerland , Carbogen Amcis will build a new API facility in several stages between 2021 and 2024 , when it will begin operations . This will comprise 12 new vessels from 630 to 4,000 litres in capacity , plus associated filtration and drying capabilities . It will also add chromatography equipment , new reactors and new laboratories to improve some of the existing technologies . The new API plant will be up to the latest quality standard , using a wide variety of different technologies , the company says .
The focus will be rather different at the new facility dedicated to custom development and manufacturing of parenteral drug products . This is located 7 km from the facility at Riom in France , which Carbogen Amcis brought from Créapharm about ten years ago . “ It has always been a dream for us to be involved in finished dosage forms and we have always believed that if you want to go into something , you had better learn about what it is all about first ,” says Griffiths . “ We bought the facility to learn about formulation and the formulation market .”
High potency production at the Huzenschwil site
New capabilities
Centrifugation is the key new capability being added at this site , according to CEO Mark Griffiths . Traditionally , the company has not had this at manufacturing scale and has only used filter-dryers . “ Some products don ’ t filter well , so having more tools like this and a liquid processing line for distillation will help ,” he says .
22 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981